You are here

EFSD European Research Programme on New Targets for Type 2 Diabetes

Supported by MSD


Geneviève Marcelin: Inserm/Sorbonne University - Paris, France
Optimising type 2 diabetes resolution maintaining adipose tissue function during weight loss

Jorge Ruas: Karolinska Institutet - Stockholm, Sweden
Anti-diabetic potential of recombinant Neurturin

Stefan Trapp: UCL - London, United Kingdom
Preproglucagon neuron activation as a novel therapeutic approach for obesity and metabolic disease


Lena Eliasson: Lund University, Diabetes Center - Malmo, Sweden
Islet hormone secretion and type 2 diabetes -focus on miRNAs as potential novel targets

Matthew Gillum: University of Copenhagen - Denmark
Long-lived lipid metabolites to regulate glucose homeostasis and hepatic steatosis

Nico Mitro: Università degli Studi di Milano - Milan, Italy
Dissecting the role of Zc3h10 in adipose tissues: a new player in type 2 diabetes onset/progression


Sebastian Barg: Uppsala University - Sweden
Regulation of insulin secretion by fusion pore dynamics

James Bowe: Kings College London - UK
Depression and SSRIs: effects on the islet adaptation to pregnancy

Anna Krook: Karolinska Institutet – Stockholm, Sweden
Metabolites and circulatory factors regulating skeletal muscle insulin sensitivity

Cedric Moro: INSERM 1048 – Toulouse, France
Natriuretic peptide deficiency in brown/beige adipocyte and type 2 diabetes development

Ruben Nogueiras: CIMUS-University of Santiago de Compostela - Spain
Regulation of autophagy by p63: implications in lipid metabolism and insulin signalling


Irene Cózar-Castellano: University of Valladolid - Spain
Role of insulin-degrading enzyme (IDE) in hepatic insulin resistance

Pirjo Nuutila: University of Turku - Finland
Insulin resistance, brain inflammation and astrogliosis studied using PET-imaging in humans (ASTRO-PET)

Shanta Persaud: King´s College London - UK
A novel human peptide to treat type 2 diabetes

Tamás Röszer:   University of Ulm - Germany
Neuropeptide FF activates adipocyte browning and alleviates insulin resistance by TLR3 inhibition

Susanna Törnroth Horsefield: Lund University - Sweden
The true target of thiazolidinediones - a new approach for treatment of type 2 diabetes

Quan Zhang: University of Oxford - UK
Investigation of the role of ER Ca2+ in the glucose regulation of glucagon secretion


Nicolas Bonnet: University Geneva Hospital - Switzerland
Osteokines new target opportunity for type 2 diabetes: effects of periostin and sclerostin on glucose metabolism

Joerg Heeren: University Medical Centre Hamburg Eppendorf - Germany
CYP7B1 – an alternative regulator for the metabolic activity of thermogenic adipocytes

Matthijs Hesselink: Maastricht University - The Netherlands
Challenging the DAGma of bioactive lipids in myocellular insulin resistance


Paul Franks: Lund University - Malmö, Sweden
Perturbation of the foetal epigenome as a dynamic model of gene-environment interactions in human type 2 diabetes

Susanne Mandrup: University of Southern Denmark - Odense, Denmark
Uncovering the nutritional impact on gene expression in pancreatic beta cells using novel in situ and genome-wide approaches

Wouter van Marken Lichtenbelt: Maastricht University - The Netherlands
Cold acclimation as a novel therapy to combat type 2 diabetes and related cardiometabolic health


Haim Cohen: Bar Ilan University - Ramat Gan, Israel
The role of SIRT6 in regulating age related metabolic diseases

David Dombrowicz: INSERM - Lille, France
Macrophage- and Treg-specific regulation of type 2 diabetes by the nuclear receptor ROR-alpha

Anders Tengholm: Uppsala University - Sweden
Epac signalling in pancreatic islet hormone secretion


Fatima Bosch: Universitat Autonoma de Barcelona - Spain
Unravelling of novel factors capable of inducing browning of WAT in vivo

Lucile Garidou: INSERM - Toulouse, France
Development of a gut microbiota-based vaccine strategy for the treatment of muscle insulin resistance

Rinke Stienstra: Radbound University - Nijmegen, The Netherlands
Restoring the balance within the IL-1 family to reduce adipose tissue inflammation and type 2 diabetes

Patrick Delhanty: Erasmus MC - Rotterdam, The Netherlands
The search for the insulin-sensitising mechanism of des-acyl ghrelin: is des-acyl ghrelin our natural metformin?


Juergen Eckel: German Diabetes Center - Duesseldorf, Germany
Adipose tissue-derived DPP4 as a mediator of the development of obesity-associated adipose tissue inflammation and type 2 diabetes

Sander Kersten: Wageningen University - The Netherlands
The entero-endocrine factor ANGPTL4 as regulator of glucose and lipid metabolism

Filip Knop: University of Copenhagen - Denmark
Delineating pancreatic and extrapancreatic effects of the incretin hormones in man

Nils Wierup: University of Lund - Sweden
Antidiabetic actions of CART

Sagen Zac-Varghese: Imperial College London - UK
A comparative study of L cells following LKB1 deletion in mice and following bariatric surgery


Gabriela da Silva Xavier: Imperial College London - UK
The role of TCF7L2 in pancreatic islet cell survival and sensitivity to GLP-1

Thierry Ferreira: Poitiers University - France
A yeast-based screening strategy of new drugs and target genes with therapeutical perspectives in type 2 diabetes

Dominique Gauguier: Cordeliers Research Centre - Paris, France
Transcription landscapes of Glis3-induced gene expression in pancreatic islets

Guy Rutter: Imperial College London - UK
The type 2 diabetes-associated secretory granule zinc transporter ZnT8 (SLC30A8) as a potential drug target

Shanna Tam: St Vincent's Institute, Fitzroy - Australia
Does LKB1 modulate wingless type MMTV integration site (Wnt) signalling in pancreatic beta cells?

Ram Weiss: Hebrew University, Jerusalem, Israel
Islet function in response to bariatric surgery in patients with pre-diabetes and diabetes

Jakob Wikstrom: Hebrew University, Jerusalem - Israel
The role of UPR-autophagy cross-talk in the regulation of beta cell fate in diabetes


Nils Billestrup: University of Copenhagen - Denmark
Regulation of beta cell growth and apoptosis by bone morphogenetic proteins and activin

Charna Dibner: University Hospital of Geneva - Switzerland
Beta cell circadian clock impact on insulin secretion and glucose homeostasis

Jochen Lang: Bordeaux University - Pessac, France
Adenylate cyclase 8: beta cell signalling, survival and glucose homeostasis

Stephan Schneider: Ruhr-University Bochum - Germany
Multimodel imaging of beta cells

Anders Tengholm: Uppsala University - Sweden
Kinetic control of insulin secretion by sub-plasma membrane cAMP signalling

Bernard Thorens: Lausanne University - Switzerland
IGF-2 and the IGF-1 receptor in the control of beta cell mass and function

Mireille Vasseur-Cognet: Paris Descartes University - France
COUP-TFll: an essential transcription factor for functional pancreatic beta cell mass


Sebastian Barg: Uppsala University - Sweden
Dynamic association of voltage-gated Ca2+ channels with docked insulin granules

Anne Grapin-Botton: Swiss Institute - Lausanne, Switzerland
In vivo imaging of endocrine islets

Jean-Christophe Jonas: Catholic University of Louvain - Brussels, Belgium
Role of beta cell hypoxia in the pathophysiology of type 2 diabetes

Hindrik Mulder: Lund University - Sweden
Melatonin and its receptors in pancreatic islets - elucidating the role of a novel type 2 diabetes gene

Romano Regazzi: University of Lausanne - Switzerland
Identification of microRNAs involved in the control of the functional beta cell mass

Susanna Törnroth-Horsefield: University of Gothenburg – Sweden
Beta cell dysfunction and type 2 diabetes - structural studies of UP and TH


Bernadette Breant: University Pierre et Marie Curie – Paris, France
The role of glucorticoids on pancreas development and the induction of type 2 diabetes: genetic approach in mice and in vitro studies

Harry Heimberg: Free University Brussels - Belgium
Activation and expansion of beta cell progenitors in the adult pancreas

Patrick Jacquemin: Louvain Catholic University – Brussels, Belgium
Beta cell neogenesis in hnf6-/- mice: characterisation and translation of the underlying mechanism to the production of beta cells in vitro

Kathrin Maedler: University of Bremen - Germany
Genetic modifications in the TCF7L2 gene regulate beta cell function and survival in type 2 diabetes

Stephan Speier: Karolinska Institutet - Stockholm, Sweden
Non-invasive in vivo imaging of pancreatic functional beta cell mass regulation 

Emmanuel Van Obberghen: Nice University Hospital - France
Beta cell failure and progression to type 2 diabetes: role of muscle-derived molecules


Amar Abderrahmani: UCHUV-Hospital - Lausanne, Switzerland
Role of human oxidised low density lipoprotein and high density lipoprotein in pancreatic beta cells: relevance for the molecular pathogenesis of diabetes

Stefano del Prato: University of Pisa - Italy
Prevalence of the TCF7L2 polymorphisms in a high risk type 2 diabetes population and their role in determining different pathogenic features as well as response to incretin-based therapy

Marc Donath: University Hospital Zurich - Switzerland
Regulation of islet inflammatory CXC chemokines and angiogenesis by the Fas-FLIP pathway

Valdemar Grill: University Hospital Trondheim - Norway
Mitochondrial plasticity and function in beta cells: effects of diabetes and hypoxia

Noel Morgan: Peninsula Medical School - Plymouth, UK
Mechanisms by which interleukin-4 protects pancreatic beta cells against pro-inflammatory cytokine induced cell death

Hindrick Mulder: Lund University - Sweden
Metabolic analysis of pancreatic beta cells

Shanta Persaud: King's College London - UK
Role of p8 in beta cell mass expansion and survival


Lena Eliasson: Lund University - Sweden
Role of miR-375 and its target proteins in insulin secretion

Jorge Ferrer: Fundacio Clinic Barcelona - Spain
Novel insights into the role of Dipetidylpeptidase IV in pancreatic beta-cell function

Françoise Homo-Delarche: Paris 7 University - France
Islet vasculopathy in type 2 diabetes: the Goto-Kakizaki (GK) rat paradigm

Leif Jansson: Uppsala University - Sweden
Blood lipids and pancreatic islet blood flow: possible pathogenetic importance for type 2 diabetes

Andreas Lechner: Ludwig-Maximilians-University - Munich, Germany
Analysis of the functional role of osteoprotegerin (OPG) in pancreatic islets

Michael Ristow: Jena University - Germany
Maintenance of pancreatic beta-cell mass by conditional knock-in of mitochondrial frataxin into diabetes-prone mice

Stephan Schneider: Ruhr-University Bochum - Germany
In vivo imaging of the islet-cell mass in normal and diabetic states

Anders Tengholm: Uppsala University - Sweden
Spatio-temporal dynamics of cAMP signals in pancreatic beta cells


Francesco Beguinot: Federico II University - Naples, Italy
The control of beta-cell function by ped/pea-15 gene and its abnormality in type 2 diabetes

Peter Bergsten: Uppsala University - Sweden
Unravelling mechanisms of beta cell glucolipotoxicity

Marc Donath: Zurich University - Switzerland
Regulation of beta-cell secretory function via FAS signalling

Jean-Christophe Jonas: Louvain Catholique University - Brussels, Belgium
Mechanisms of beta cell glucotoxicity

Erik Renström: Lund University - Sweden
Identification of candidate genes for type 2 diabetes: Molecular investigations of mechanisms for defective insulin secretion related to a major species-conserved susceptibility locus

Emmanuel Van Obberghen: INSERM - Nice, France
Role of SOCS proteins in beta cell function and survival